The opportunity and the risk
Patient registry data is extremely valuable to the pharmaceutical industry. A disease registry with natural history data, verified diagnoses, stored samples, and an engaged community can:
- Serve as a comparator arm for single arm clinical trials
- Provide pre-screened participants for trial recruitment
- Support regulatory submissions as real world evidence
- Inform trial endpoint selection and outcome measure development
- Enable postmarket surveillance studies
This creates leverage for your organization. You hold something valuable. The question is how to structure partnerships that advance science and benefit participants, without compromising your independence or your participants' trust.
Types of industry engagement
Data licensing
A company pays for access to your registry data, either aggregate analyses, deidentified individual records, or (with additional consent) identified data.
Key protections:
- You retain data ownership; the license is time-limited and purpose-limited
- Use restrictions must be explicit: no reidentification, no secondary commercial use, no data sale
- Define the expiration and data destruction obligations
- Reserve the right to publish independent analyses
Natural history partnership
A company funds registry operations in exchange for being able to use your natural history data to support their regulatory submission.
Key protections:
- This is a research partnership, not a sponsorship, maintain scientific independence
- Your SAB (not the company) controls data element selection and analysis plans
- You retain publication rights
- Any FDA meetings where registry data is presented should include advocacy organization representation
Recruitment partnership
A company compensates your registry for identifying and referring eligible participants to their clinical trial.
Key protections:
- Referral must be genuine and patient-centered, never pressure participants to enroll in trials
- Compensation should be transparent and fair market value
- Participants must understand the distinction between registry participation and trial enrollment
- Your organization should never receive per-enrollment payment in ways that create incentive to over-refer
Sponsored registry
A company funds the creation of a registry from scratch, with the explicit goal of generating data for their regulatory program.
This arrangement requires the most careful structuring. Ensure:
- Governance remains with the advocacy organization
- An independent SAB controls scientific decisions
- All participants are informed of industry funding in the consent document
- A firewall exists between your organization's advocacy activities and the sponsored registry
Negotiating the data use agreement
The DUA is the most important document in an industry partnership. Key terms to negotiate:
| Term | Your position |
|---|---|
| Data ownership | Your organization owns the data, always |
| Publication rights | You retain the right to publish; company may have limited review period (30 to 60 days) for confidentiality concerns only, not to suppress findings |
| Reidentification prohibition | Absolute prohibition |
| Secondary use | Prohibited without separate agreement |
| Audit rights | Right to audit data use compliance |
| Term and termination | Define what happens to data upon agreement expiration |
| Intellectual property | Data generated by your registry is your IP; discoveries made using your data by the company belong to the company (define clearly) |
| Transparency | Require disclosure of the partnership to FDA and in publications |
Protecting participant trust
Your community's trust is your most valuable asset, worth more long term than any individual industry partnership. Maintain it by:
- Being transparent with participants about industry partnerships in your consent document
- Publishing an annual transparency report disclosing funding sources
- Never allowing industry partners to contact participants directly
- Maintaining independent scientific governance
- Being willing to decline partnerships that conflict with participant interests